retatrutide phase 2 trial obesity triple agonist Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide hits 28% weight loss

In a resignation message shared publicly by the president, Makary defended his record, citing what he described as dozens of major reforms, including sharply shortened drug review timelines, new guidance for psychedelic therapies, a plausible mechanism pathway for rare disease drugs, and changes to estrogen labelling

Stay Engaged With Your Healthcare Team Your healthcare providers are your partners in making the journey work for you

This prevents the false dawn errorassuming a market is open when only the primary patent has expired

Lin, J., Della-Fera, M

Injecting the drug allows it to continuously be active in your body for longer periods of time

A new Ozempic rival helps patients lose fat, but keep their muscle the holy grail for a weight-loss drug It's the holy grail for a weight-loss drug: Stay strong, but lose the fat